Successful Utilization of the GLP-1 Receptor Agonist Semaglutide in Treating the Manifestations of Recalcitrant Celiac Disease

Authors

  • David S H Bell
  • Terri Jerkins

Abstract

A refractory case of abdominal swelling (pseudoascites) due to celiac disease which did not respond to monotherapy with a gluten-free diet and for which treatment with traditional immunosuppressives was refused is described. Based on reports of the anti-inflammatory actions of the GLP-1 receptor agonist, semaglutide, weekly subcutaneous injections of semaglutide were added to the gluten-free diet with rapid and obvious success. Semaglutide and perhaps other GLP-1 receptor agonists should be considered for use as a largely safe anti-inflammatory drug in other autoimmunopathies and inflammatory states.

Downloads

Published

2025-09-29

How to Cite

Bell, D. S. H., & Jerkins, T. (2025). Successful Utilization of the GLP-1 Receptor Agonist Semaglutide in Treating the Manifestations of Recalcitrant Celiac Disease. Archives of Clinical and Biomedical Research, 9(5), 392–395. Retrieved from https://fortunejournals.org/ojs/index.php/acbr/article/view/15136